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The phenomenon of spontaneous regression and remission from cancer has been observed by many physicians and was described in
hundreds of publications. However, suggestive clues on cause or trigger are sparse and not substantiated by much experimental
evidence. In this review, literature is surveyed and summarised and possible causes are discussed. At least in a larger fraction of cases a
hefty feverish infection is linked with spontaneous regression in time and is investigated as putative trigger. Epidemiological and
immunological evidence is put into perspective. An online forum to discuss the possible application of fever therapy in the future can
be accessed at http://bioinfo.tg.fh-giessen.de/fever-and-cancer.
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Spontaneous regressions and remissions from cancer have been
recognised since the diagnosis of cancer became a science.
Rohdenburg, a medical director at Columbia University, wrote in
1918: ‘It can be definitely asserted that regressive changes varying
from a temporary standstill to the complete disappearance of the
tumour, whether it be of epithelial or connective tissue origin, may
occur at any age period, in either sex, and irrespective of the
location of the growth’. On the other hand, large fractions of
clinicians over large fractions of the century disregarded the
phenomenon or denied that its existence has been proven beyond
doubt. Although even a quick glance into the literature must
convince us that unexplained healings from cancer happen, it is a
rare event and, most importantly, the phenomenon of spontaneous
healing in cancer remains almost without clue. Here I survey
literature on spontaneous regression and remission and try to
align with contemporary immunology and epidemiology.
DISCUSSION
Spontaneous regressions
The literature on spontaneous regression and remission consists of
numerous case studies and few reviews (Rohdenburg, 1918; Boyd,
1966; Everson and Cole, 1968; Stephenson et al, 1971; Challis and
Stam, 1990). Two of these reviews appeared as books (Boyd, 1966;
Everson and Cole, 1968). The reviews of Stephenson et al (1971)
and of Challis and Stam (1990) are of particular importance, since
they were published in scientific journals and passed peer review.
Stephenson et al were the first to use a computer for statistical data
analysis on spontaneous regression. They included the cases
mentioned by Everson and Cole and added 48 case reports to a
final number of 224 cases (Stephenson et al, 1971). Challis and
Stam re-reviewed 61 cases mentioned in Boyd (1966), re-reviewed
176 cases mentioned in Everson and Cole (1968) and added 265
articles covering 504 case studies found by manual and computer
searches for the period 1966–1987 (mean 24 cases per year).
For the subsequent period 1987–2003, a PubMed query on case
reports of spontaneous regressions/remissions/resolutions delivers
136 hits (Query, 2004) (mean 10 reports per year). Since some of
the case reports covered more than one patient, we can state a
small but ongoing rate of about 1–2 dozen reported cases per year
over the past 40 years, with perhaps decreasing tendency.
Regressions and remissions were not always permanent;
however, in a considerable number of cases they were long lasting
or even cures. According to the Everson and Coles study, in 57/176
(33%) cases the regression lasted more than 5 years; the extended
study of Challis and Stam reports 25% patients alive after 5 years,
where this is a lower margin, since for 20% of patients no such
record could be obtained. Hence, spontaneous regressions can
save lives.
The important work of Challis and Stam covering 741 selected
cases from the period 1900–1987 has not fuelled much discussion.
Presumably a melange of reasons is accountable, namely
misdiagnosis, rareness, denial and unexplainability.
First, malign neoplasms were sometimes misdiagnosed, with
higher likelihood for reports from the early 20th century. Attempts
to avoid false-positive reports (non-neoplasm reported as neo-
plasm) increases the risk of introducing false-negatives (filtering
away true malign neoplasms as misdiagnosis); yet, the authors
attempted to be on the safe side. Everson and Cole applied
rigorous standards emphasizing clear histologic confirmation,
which led them to drop a majority of case reports from
consideration. Also, lymphomas and leukaemias were excluded
because of the natural changes in growth rate these malignancies
undergo, and retinoblastomas were excluded because histological
evidence was rarely available. Chalis and Stam again emphasised
clear histological confirmation, but included lymphoma and
retinoblastoma.
Second, rareness: Omitting to read the case reports but looking
at numbers only – less than 1000 published cases in a century in
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www.bjcancer.comwhich cancer is among the four main causes of death in
industrialised nations – might cast doubt whether spontaneous
regression is of any significance with respect to research, even if
we assume a large number of unreported cases. A large fraction of
unknown cases must be assumed for obvious reasons. Cases will
not be observed when the patients after improvement of their
condition did not show up in the clinic any more. Observed cases
will not be reported, when the responsible physician (i) did not
consider the case relevant, (ii) was unable to make sense out of it,
(iii) could not rule out effective prior treatment, (iv) was not
literate enough or did not take the effort to write a report. An
estimation of the rate of spontaneous remission can only be
approximate due to lack of solid data. If, for a very coarse estimate,
one assumes 50 new cancer cases in a population of 1000 per year,
a collective average population size of 600 million people in the US,
Europe and Japan and a 100-fold underestimate of spontaneous
regression given by the number of published cases (653 in the
period 1966–2004), only about 1–10 spontaneous remissions per
1 million cancer cases can be assumed. Yet, exceptional cases can be
instructive. In HIV research, long-term nonprogressors (LTNP) –
infected people who do not progress into full AIDS for long
periods – are a small but interesting cohort of patients. One such
cohort consists of individuals with a mutation in both alleles for
the CCR5 receptor. CCR5 was identified as one of the receptors
used by the virus for entry and is now target of intense research on
entry inhibitors, a novel class of drugs (Vermeire and Schols,
2003).
Third, rebuffal. We have to admit that over a large portion of the
century a large fraction of clinical oncologists would simply deny
any healing capacity of the human body with respect to cancer.
Professor Bauer, one of the founders of the German Cancer
Research Institute (DKFZ) in Heidelberg, in his founding talk for
the institute in 1965 claimed that ‘the human body has no cancer
fighting capabilities’. Such a preoccupation cannot be apt to gain
scientific insight.
Fourth, unexplainability. Everson and Cole in 1968, in their
summary, offered as explanation for spontaneous regression the
following: ‘In many of the collected cases [y] it must be
acknowledged that the factors or mechanisms responsible for
spontaneous regression are obscure or unknown in the light of
present knowledge. However, in some of the cases, available
knowledge permits one to infer that hormonal influences probably
were important [y]. In other cases, the protocols strongly suggest
that an immune mechanism was responsible [y]’. Challis and
Stam in 1989, even more at a loss, survey ‘In summary, we are left
to conclude that, although a great number of interesting and
unusual cases continue to be published annually, there is still little
conclusive data that explains the occurrence of spontaneous
regression.’ This lack of understanding persists until today, as
shown by an arbitrarily chosen example published in a high impact
journal. In an article in the Proceedings of the National Academy
of Sciences, the authors wrote in 2003 (Cui et al, 2003): ‘Despite
efforts over many decades, the mechanism(s) of spontaneous
regression in humans and animals has remained elusive.’
Apparently, 20th century medicine provided perplexingly few
explanations facing this intriguing phenomenon. Yet, an unusually
strong immune reaction might play a role.
Tumour immunology
Cancer patients usually carry tumour-reactive T-cells, that is,
T-cells that recognise tumour cell antigens. It was known early on
not only that tumours are invaded by defence cells but also that the
number of invading cells and survival rate can correlate (Black
et al, 1956). This exciting observation published in 1956, however,
did not lead into any research activity aimed at strengthening the
defence capacities of the body, but rather was overshadowed by
hopes and hypes offered by the emerging chemotherapy. The first
molecular identification of tumour antigens was described in 1988
in mice (Plaen et al, 1988) and 1991 in humans (VanderBruggen
et al, 1991). Today, it is certain that tumour-specific T-cells can be
found in high numbers among tumour-infiltrating lymphocytes
(TIL) (Romero et al, 1998), but this T-cell response usually does
not translate into healing progress. Tumour antigen reactivity
usually is weak, these T cells are naturally tolerant of host cancer
cells (Pardoll, 2002). Obviously, cancer cells derive from self and
appear, in general, more self than non-self to the immune system.
Numerous attempts have been made to break this tolerance in
order to establish a full-blown T-cell attack against tumour
burden, with some success regarding induction of regression but
limited success regarding curation (see Jaeger et al (2002) for a
review on vaccination strategies). It has been suggested that many
of these attempts failed because only a particular part of the
immune repertoire has been spoiled by these experiments, while
a concerted effort is required. For instance, in one advanced
experimental setting, dendritic cells (DC) loaded with known
melanoma peptide antigens were used to prime T-cell clones from
melanoma patients in vitro. Growth and clonal expansion of a
highly reactive CD8 clone and backtransfer to patients resulted in a
dramatic homing of re-injected cells at metastatic sites, but this
increased tumour cell recognition by T cells did not propagate into
clinical benefit to the patients (Yee et al, 2002), since antigen-
negative tumour cells were out of target and escaped. Because a
combination of CD4 and CD8 responses is required for sustained
memory and antitumour activity (Pardoll and Topalian, 1998), a
panel of T-cell clones is probably needed to address the genetic
and antigenic heterogeneity of tumour cells (Loeb, 2001). Along
this line, in another study from 2002, polyclonal T cells were used
with greater success. TIL of mixed CD4 and CD8 clonality were
used for expansion and re-application to patients, and 6/13
patients experienced partial responses (Dudley et al, 2002). The
procedure of extracting TILs, priming and expansion in vitro and
application to the host over longer periods is technically
demanding and laborious, thus expense will be a limiting factor
for the design of larger clinical trials.
Rather than extracting reactive T-cells from an individual
patient, another broadly explored strategy was to define peptide
antigens characterising an individual tumour and vaccinating
either using the peptide directly or by loading autologous DC with
peptide. Only one or a small number of antigens was used in these
trials, and again the clinical outcome was limited, with more
favourable outcomes for DC-loaded vs peptide-alone strategies, but
response rates rarely exceeding 30% (Parmiani et al, 2002) and
uncertain benefit on survival. It should be noted that all tumour
antigens used in clinical vaccination trials so far are not
canonically tumour specific, but are naturally expressed either in
a certain state of differentiation like embryogenesis or are
expressed in immunoprivileged sites such as testis or are even
expressed at a low level in normal tissue. It may be that it is not
one or a few antigens that distinguish tumour from normal tissue,
but rather an un-normal composition of antigens. In the latter
case, a larger spectrum of antigens – defined or undefined – from a
patient’s individual disease case must be used for any vaccination
strategy. For larger or inoperable tumours, a longer therapy
regimen might be advisable, which must address the problem of
lesions genetically varying in time, such that antigenic drift has to
be considered by regularly re-adjusting the panel of antigens in
use. In a recent draft, Rammensee and co-workers outlined such a
sophisticated strategy including differential gene expression and
HLA analysis comparing an individual patient’s normal and
tumour tissue using DNA microarrays, bioinformatic data analysis
to define potential antigens, on-the-spot clinical grade peptide
synthesis of antigens, vaccination and monitoring (Rammensee
et al, 2002). If antigen drift or genetically distinct cell layers within
the tumour are to be considered, this procedure has to be repeated
several times during an individual patient’s therapy. Again, such a
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be applicable only on a very limited number of patients in the near
future. It must be noted that those tumours which lost most of
their MHC surface molecules and which can only be recognised by
natural killer cells cannot be addressed by this strategy.
In the following, I will assume that in cases of spontaneous
regression tumour tolerance has been broken and regression was
the result of a full-blown immune attack. I will collect evidence that
high fever was a time correlate in many cases of spontaneous
regression, and will argue that fever might play a dominant role in
helping the immune system to overcome tolerance.
Fever and spontaneous regression
A correlation between regression and fever was noted long ago, but
forgotten later on. Rohdenburg (1918) stated, ‘The greatest
number of spontaneous regressions have occurred following
incomplete surgical removal of the tumour, next in order of
frequency during some acute febrile processy’. Even for the first
group he remarks, ‘In some of the histories of this group it is
definitely stated that immediately after operation a high tempera-
ture developed, which continued without remission for several
days’, so he distinguished infectious and postoperative fever. He
collected 302 cases of regression, with 77 cases including 44
complete remissions belonging to ‘those reports which stand a
most rigid scrutiny’ of correct diagnosis. In 27/302 cases the
‘assigned cause of absorption’ was acute infection, in 69 cases it
was ‘incomplete operation’, which, according to Rohdenburg’s
observation, was often accompanied by high temperature of
several days duration. The most frequent infection was erysipelas,
an infection causing particularly high fever and producing
exotoxins that can function as superantigens, giving rise to
polyclonal expansion of T-cells. But also small-pox, pneumonia,
malaria and acute tuberculosis were observed. Diamond and
Luhby (1951) reported 26 spontaneous remissions in a cohort of
300 cases of childhood leukaemia, 21/26 (80%) were accompanied
by infection. Everson and Cole, in their 1966 review, noted in 8/176
cases a severe infection preceding regression (Everson and Cole,
1968; Cole, 1981); however, they probably overlooked some
concurrent infections, since Stephenson et al, in their 1971
publication, used the same 176 cases and added 48 cases, but
found that in 62/224 cases (28%) either an infection or a persistent
temperature elevation was reported prior to regression (Stephenson
et al, 1971). Only vague indication about the involvement of
febrile processes is given in the review of Challis and Stam (1990),
who state that infection and ‘operative trauma’ were reported in
about 4% of the cases. In melanoma, a particular immunogenic
variant of cancer, about 1/400 patients experience a spontaneous
regression. In a collection of 68 well-documented cases of
regression from melanoma, Maurer and Koelmel (1998) found 21
cases with febrile infection preceding regression (31%), in a
majority of cases (nine) identified as erysipelas.
The rate of fever concurrent with regression was most likely
biased by the awareness of the authors, both of original reports
and reviews. Fever, in particular during the second half of the 20th
century, which is characterised by heavy use of antibiotics, was
regarded unequivocally by main-stream medicine as an unneces-
sary, weakening state which should be avoided or prevented. The
situation has not changed much today. For this reason, if one
wants to estimate the rate of fever preceding regressions and
remission, one must assume a rate higher than the approximately
30% rate indicated by the Stephenson review, or even much higher
for cancers of haematopoetic origin (80%) as indicated by the
review of Diamond and Luby, because preceding fever most likely
often was not reported. If fever often precedes regressions, there
might be a causative connection. This hypothesis can be
substantiated by evidence from studies unrelated to spontaneous
regression and remission.
Fever and bacterial extracts
Professor Busch in 1868 introduced the infection of cancer patients
by purpose as a novel strategy to treat cancer. He achieved a
dramatic regression with his first patient using live Streptococcus
pyogenes bacteria, the pathogen leading to erysipelas, published in
the German Journal ‘Berliner Klinische Wochenschrift’ (Busch,
1868). Beginning in 1891, this strategy was exploited by Coley, who
had some reading knowledge of German (Hall, 1998). Coley
systematically applied Streptococcus pyogenes extracts – later called
‘Coley’s toxin’ – to cancer patients and achieved a remarkable rate
of regressions. A retrospective compilation of cases considered
inoperable at the time of treatment between 1891 and 1936, which
was conducted by Wiemann and Starnes (1994, Table 2),
determined a remission rate of 64% (108/170) and a 5-year
survival rate of larger than 44%. Coley used to inject his extract
once or twice a week over a period ranging from a few weeks to
several months. His method became quite famous and was tested
on hundreds of patients by him and contemporary physicians, but
overshadowed by the development of X-ray treatment which was
regarded to be much more powerful and of broader applicability.
Unfortunately, Coley failed to establish a standard procedure but
rather varied the regimen (extract preparation, treatment duration,
injection frequency, injection site, dosage) throughout his career,
making it difficult to compare his case studies and to pinpoint
crucial parameters. His daughter Helen Coley-Nauts re-examined
his case studies with respect to differences in bacterial preparation
and clinical outcome (Nauts and McLaren, 1990). It is apparent
from her publications, but had escaped Coleys attention, that there
was a correlation between the potency of a particular extract
preparation to induce high fever and rate of curation: 3/13
different preparations had the highest rate of curation (survival
longer than 10 years) and were the most powerful in inducing
febrile reactions. Also, better clinical response correlated with
duration of treatment: if the injections were given over 6 months,
an astonishing 80% of inoperable sarcoma of soft tissues survived
for 5–88 years (Nauts and McLaren, 1990).
Standardised commercial bacterial extracts similar to Coley’s
toxin appeared on the market in the 50s and 60s (MBV-mixed
bacterial vaccine, Bayer; Vaccineurin, Suedpharma; Picibanil, OK-
432, Chugai). Attempts to repeat his successes half a century later
using these products were of mixed benefit. In few of these studies
particular attention was paid to the induction of high fever
possibly reaching 401C on one side and long treatment over at least
several weeks on the other side, both of which appear to correlate
with improved outcome (for reviews, see Nauts and McLaren,
1990; Hobohm, 2001). More important, in contrast to Coley’s time,
most of the patients treated with commercial extracts had prior or
concurrent chemotherapeutic treatment with obvious immuno-
compromising effects, potentially diluting the effect of an
immunostimulatory therapy.
Epidemiology
Since cancer is usually a slowly progressing disease with
occasionally long periods of dormancy, putative beneficial fever
effects should also precipitate as preventive efficacy. This can
indeed be found. In a cohort of 603 melanoma patients compared
to 627 population controls, an inverse correlation was found
between melanoma risk and number of recorded infections on the
one hand and between melanoma risk and fever height on the
other hand, leading to a combined reduction of melanoma risk of
about 40% for people with a history of three or more infections
with high fever above 38.51C (Koelmel et al, 1999). Mastrangelo
et al (1998) report a striking inverse correlation between the
number of infections and mortality from tumours in Italy in the
period 1890–1960: every 2% reduction in the number of infectious
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Fever immunology
How could fever act on cancer cells? Fever is used by organisms
as diverse as fish, amphibians, reptiles and mammals (see for
reference Basu and Srivastava, 2003). Since fever is metabolically
expensive, it must provide substantial advantage to the host.
Surprisingly little is known about immunological effects mediated
by fever, a lack of understanding that might be attributable in part
to the common ignorance in clinical practice with respect to
benefits fever might provide. Post-operative infections can be
prolong survival: patients developing empyema after lung cancer
surgery have improved 5-year survival (50% (n¼18) vs 22%
(n¼411)) (Ruckdeschel et al, 1972). In this light, it seems
unfortunate that fever is usually suppressed in hospital routine.
Effects of hyperthermia, that is, heat applied externally resulting
in less and different cytokine production compared to real fever,
have been examined to some extent. It has been shown in vitro that
DC treated with fever-like heat (411C, 6h) was significantly
superior compared to non-heat-treated DC in stimulating T cells
both in the presence or without antigen. Heat treatment of DC
activates NF-kB, a transcription factor regulating a number of
immunological genes. Similar results were obtained in vivo in mice
using hyperthermia (411C, 1h) as heat treatment (Basu and
Srivastava, 2003). Tumour cells are more vulnerable to heat than
normal cells and undergo necrosis to a larger extent (Dickson,
1979; Trieb et al, 1994). Heat shock protein HSP90 released from
cells as a result of necrotic death has been shown to cause
maturation of DC (Basu et al, 2000). Immunogenic HSP–peptide
complexes are displayed to a larger extent on cancer cells after heat
treatment at least in some cancers (Udono and Srivastava, 1993;
Multhoff et al, 1995), an interesting feature since these complexes
can activate natural killer (NK) cells (Botzler et al, 1996), offering a
second defence line independent of MHC-restricted immunogeni-
city provided by CD4þ/CD8þ T cells. Perhaps fever can generate
a missing costimulatory signal via DC needed by resting tumour-
specific T cells for full activation, followed by partial or complete
‘spontaneous’ regression in an established tumour, to eradication
of dormant cancer cells in a young tumour (prevention) or to
eradication of residual cancer cells after surgery (improved
survival after postoperative infection). The involvement of
adjuvants should provide additional therapeutic options, as might
strategies to block inhibitory pathways of T-cell activation
temporarily (Leach et al, 1996; Rubinfeld et al, 1997).
Since there is much evidence that fever alone can have beneficial
effects, experiments using pyrogenic cytokines for treatment of
cancer (e.g. interleukin (IL)-1, IL-6, tumour necrosis factor (TNF),
ciliary neurotropic factor (CNTF), interferon-(IFN)-alpha) should
discuss cytokine and fever effects separately.
Clinically controlled induction of fever as part of therapy
regimen should be re-considered, now carefully addressing fever
height, fever duration, fever schedule and distance in time between
fever and chemotherapy, before or after.
CONCLUSION
A large fraction of spontaneous regressions and remissions
described in the literature was preceded by a hefty feverish
infection. The hypothesis that fever can have therapeutic value can
be brought in line both with successful historical attempts to apply
fever using bacterial extracts and with immunological evidence.
Putative beneficial effects of fever should as well act preventive,
and indeed epidemiological studies show that a personal history of
feverish infections reduces the likelihood to develop cancer later.
Immunological strategies to break cancer cell tolerance should
be individualised rather than generic. Fever induction will
necessarily induce an individual response, which even addresses
the problem of antigenic drift in time. Today we should be able to
induce and control fever much better than 100 years ago. The
discussion should be re-opened if and how to best scrutinise fever
therapy in the future (see http://bioinfo.tg.fh-giessen.de/fever-and-
cancer for online discussion).
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